What would be your approach to initial treatment of a patient with standard-risk myeloma unwilling to undergo autologous stem cell transplant, if practicing in a resource-limited setting?  

For non-transplant candidates or patients unwilling to have transplant with standard risk MM, these are my 2 choices: RVd: len/velcade/dex: based on the SWOG S077 compared to Rd: Durie et al., PMID 28017406. Dara Rd: Daratumumab/Revlimid/dex: based on the MAIA study compared to Rd: Facon et al., P...